Hospital Acquired Infection Control Market Size, Share, Growth, and Industry Analysis, By Type (Catheter-associated Urinary Tract Infections (CAUTIs),Surgical Site Infections (SSIs),Central Line-associated Bloodstream Infections (CLABSIs),Respiratory Infections), By Application (Hospitals and ICUs,Outpatient Care Centers,Long-term Care Facilities (LTCFs)), Regional Insights and Forecast to 2035

Hospital Acquired Infection Control Market Overview

The global Hospital Acquired Infection Control Market is forecast to expand from USD 6415.15 million in 2026 to USD 6601.19 million in 2027, and is expected to reach USD 8292.58 million by 2035, growing at a CAGR of 2.9% over the forecast period.

The Hospital Acquired Infection Control Market responds to a global burden where approximately 1 in 10 hospitalized patients acquire a healthcare-associated infection (HAI) in low-and-middle-income settings and an estimated 4.3 million patients in the EU/EEA acquire at least one HAI annually in recent prevalence surveys. Major HAI types—CAUTIs, SSIs, CLABSIs and respiratory infections—account individually for tens of thousands to millions of incidents per year, and antimicrobial-resistant HAIs number roughly 136 million globally per year in recent WHO analyses. These prevalence and AMR figures underpin the Hospital Acquired Infection Control Market Analysis and Hospital Acquired Infection Control Market Report demand for surveillance, disinfection, diagnostics and stewardship solutions.

In the United States the Hospital Acquired Infection Control Market is driven by NHSN surveillance figures showing on any given day about 1 in 31 hospitalized patients has at least one HAI, and historic estimates identified roughly 687,000 HAIs in U.S. acute care hospitals in past national surveys. CDC reporting shows device-associated infections (CLABSI, CAUTI) and SSIs account for tens of thousands of incidents annually, with CLABSIs estimated at roughly 41,000 cases per year in one consolidated U.S. estimate cited in 2023 analyses. U.S. hospitals increasingly adopt bundle programs, with 60–80% compliance targets for many prevention bundles, driving procurement of diagnostics, disinfection systems and surveillance platforms in the Hospital Acquired Infection Control Market Outlook.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 72% of hospital infection-prevention programs cite surveillance, disinfection and rapid diagnostics as the principal procurement drivers for the Hospital Acquired Infection Control Market.
• Major Market Restraint: 24% of hospital procurement officers list constrained infection-control budgets and staffing shortages as the main restraint on purchases.
• Emerging Trends: 41% of new product launches in 2023–2024 featured rapid point-of-care diagnostics, automated disinfection or antimicrobial surface technologies.
• Regional Leadership: North America accounts for approximately 34% of advanced-technology adoption in hospital infection control, while Asia-Pacific accounted for roughly 36% of global HAI control procurement volume in 2023.
• Competitive Landscape: Top 10 vendors account for about 55% of the high-end device and diagnostic spend in the Hospital Acquired Infection Control Industry Report segment.
• Market Segmentation: Disinfection systems, diagnostics, surveillance software and consumables represent roughly 4 major spend buckets, with consumables accounting for about 42% of unit volume purchases.
• Recent Development: 19% year-on-year increase in adoption of UV-C and vapor hydrogen peroxide automated room disinfection systems was observed in hospital retrofits during 2023–2024.

Hospital Acquired Infection Control Market Latest Trends

Recent Hospital Acquired Infection Control Market Trends show accelerated adoption of digital surveillance, rapid diagnostics and automation: about 28% of acute hospitals adopted enhanced electronic HAI surveillance modules in 2023, and 19% more facilities purchased automated room-disinfection systems in 2024 compared to 2022. Rapid molecular diagnostics gained traction with 35% of larger hospitals piloting point-of-care pathogen panels in 2023–2024, and laboratories reported an approximate 22% rise in demand for rapid pathogen ID consumables over that timeframe. Antimicrobial stewardship programs expanded: 44% of hospital systems reported new stewardship hires or reallocated resources in 2023. In parallel, investment in environmental monitoring rose by 16%, with about 42% of infection control teams adopting adenosine triphosphate (ATP) or microbiological surface testing as routine checks. The Hospital Acquired Infection Control Market Research Report and Hospital Acquired Infection Control Market Analysis indicate that procurement cycles now prioritize integrated bundles (surveillance + diagnostics + disinfection) accounting for roughly 25% of new contracts awarded in 2024.

Hospital Acquired Infection Control Market Dynamics

DRIVER

"Rising incidence of HAIs and antimicrobial resistance increases demand for infection control solutions"

The principal market driver for the Hospital Acquired Infection Control Market is the persistent HAI incidence: WHO and national surveillance indicate that on average 1 in 10 patients in low-and-middle-income hospital settings acquire an HAI, while European prevalence surveys estimate 4.3 million HAIs annually in EU/EEA hospitals. Antimicrobial resistance compounds the issue: approximately 136 million antibiotic-resistant HAIs are estimated annually, translating into expanded demand for rapid diagnostics, advanced disinfection, and stewardship platforms. 

RESTRAINT

"Budget constraints and workforce shortages limit adoption of advanced infection control technologies"

A notable restraint is operational and capital budget limits: about 24% of infection prevention managers reported budget cuts or flat budgets in 2023 that delayed purchases of high-end systems like automated decontamination robots or point-of-care molecular devices. Workforce shortages also matter: 33% of hospitals reported unfilled infection preventionist roles in 2023, constraining program implementation.

OPPORTUNITY

"Integration of rapid diagnostics, AI surveillance and green disinfection creates cross-sell potential"

Opportunities in the Hospital Acquired Infection Control Market include integrated service contracts and multi-product bundles: about 25% of new procurement tenders in 2023 requested combined surveillance-diagnostic-disinfection packages. Artificial intelligence and predictive analytics pilots represented roughly 18% of national hospital networks in 2023 and are expanding, with 12% of those moving towards production deployment in 2024.

CHALLENGE

"Fragmented procurement, regulatory complexity and evidence requirements slow commercial scale-up"

Key challenges in the Hospital Acquired Infection Control Market are fragmented procurement and the need for robust clinical evidence: 62% of purchasing decisions require local clinical trials or real-world evidence prior to roll-out, with trial durations averaging 9–18 months. Regulatory and validation requirements for diagnostics (e.g., molecular panels) added 6–9 months to time-to-market in many jurisdictions; 41% of vendors reported extended regulatory review times in 2023–2024.

Hospital Acquired Infection Control Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

The Hospital Acquired Infection Control Market Segmentation spans product types and applications: primary product categories include diagnostics (molecular and culture), disinfection systems (automated and manual), surveillance software, consumables (PPE, disinfectants) and training/services.

BY TYPE

Catheter-associated Urinary Tract Infections (CAUTIs): CAUTIs remain a significant HAI subtype: in many surveillance datasets CAUTI rates ranged from 1.4 to 8.0 infections per 1,000 catheter days in different institutions, and CAUTI prevention bundles (timed catheter removal, aseptic insertion) reduced incidence by 40–60% in published programs. The Hospital Acquired Infection Control Market for CAUTI products includes closed catheter systems, silver-coated catheters and urinary diagnostics; about 18–22% of urinary catheter purchases in 2023 were for antimicrobial or coated devices in higher-risk units. Adoption of CAUTI surveillance modules increased by 14% in 2024 among large hospital systems.

The CAUTIs segment is expected to hold a significant market share with a market size of USD 1843.29 million in 2025, projected to reach USD 2312.84 million by 2034, growing at a CAGR of 2.6%, driven by increased catheter use in critical care units.

Top 5 Major Dominant Countries in the CAUTIs Segment

• United States: The U.S. market stands at USD 642.17 million in 2025, reaching USD 809.26 million by 2034, with a CAGR of 2.7%, supported by advanced infection surveillance systems.
• Germany: Germany’s market is USD 238.94 million in 2025, expected to hit USD 295.12 million by 2034, at a CAGR of 2.5%, driven by robust hospital hygiene standards.
• China: China records USD 202.33 million in 2025, increasing to USD 258.11 million by 2034, with a CAGR of 2.7%, fueled by the expansion of tertiary hospitals.
• India: India’s CAUTIs market is USD 168.54 million in 2025, projected to reach USD 214.27 million by 2034, growing at a CAGR of 2.6%, owing to growing ICU capacities.
• United Kingdom: The UK holds USD 158.43 million in 2025, expected to reach USD 199.34 million by 2034, with a CAGR of 2.5%, supported by infection control policy enforcement.

Surgical Site Infections (SSIs): Surgical Site Infections account for substantial morbidity: SSIs represent roughly 20–30% of HAIs in surgical wards and are associated with 2–20 additional hospital days per affected patient in many analyses. Hospitals implemented perioperative antibiotic timing bundles and wound-care protocols, which reduced SSI rates by 25–50% in multiple studies; over 60% of tertiary centers in 2023 had standardized SSI surveillance pathways. Devices and consumables addressing SSIs—antimicrobial sutures, wound irrigation systems and single-use surgical drapes—captured 28% of device-market spend within the Hospital Acquired Infection Control Market in 2023.

The SSIs segment holds strong growth potential with a market size of USD 1676.43 million in 2025, projected to reach USD 2184.61 million by 2034, at a CAGR of 3.0%, driven by the rise in surgical procedures globally.

Top 5 Major Dominant Countries in the SSIs Segment

• United States: The U.S. market stands at USD 574.12 million in 2025, growing to USD 755.83 million by 2034, at a CAGR of 3.1%, led by hospital safety and sterilization advances.
• France: France’s market size is USD 218.67 million in 2025, reaching USD 283.74 million by 2034, growing at 3.0% CAGR, fueled by surgical infection prevention programs.
• China: China’s SSIs market is USD 204.58 million in 2025, estimated to reach USD 268.24 million by 2034, with a CAGR of 3.1%, driven by growth in public hospitals.
• India: India records USD 179.48 million in 2025, rising to USD 235.67 million by 2034, growing at a CAGR of 3.0%, supported by improved infection monitoring systems.
• Germany: Germany’s market is USD 164.87 million in 2025, projected to reach USD 214.32 million by 2034, growing at CAGR 2.9%, boosted by surgical care safety protocols.

Central-Line Associated Bloodstream Infections (CLABSIs): CLABSIs are critical: estimates suggest roughly 41,000 CLABSI cases occur annually in some national estimates, and bundle implementation (sterile insertion kits, chlorhexidine skin prep) often reduced CLABSI incidence by 40–70% in high-adherence programs. Central-line consumables (antimicrobial dressings, impregnated catheters) saw 24% unit growth in procurement among ICU buyers in 2023, and adoption of insertion checklist compliance monitoring reached 54% of large hospitals.

The CLABSIs segment holds a market size of USD 1417.82 million in 2025, projected to reach USD 1795.12 million by 2034, at a CAGR of 2.7%, attributed to greater awareness of intravenous line sterilization.

Top 5 Major Dominant Countries in the CLABSIs Segment

• United States: The U.S. market is USD 498.24 million in 2025, expected to reach USD 639.27 million by 2034, growing at a CAGR of 2.8%, driven by advanced hospital monitoring systems.
• Germany: Germany’s CLABSIs market stands at USD 186.45 million in 2025, rising to USD 233.57 million by 2034, growing at 2.7% CAGR, aided by improved critical care practices.
• China: China’s market is USD 163.83 million in 2025, projected to reach USD 206.58 million by 2034, growing at 2.7% CAGR, led by hospital expansion and training programs.
• Japan: Japan holds USD 141.54 million in 2025, expected to reach USD 178.29 million by 2034, at a CAGR of 2.6%, supported by high healthcare standards.
• India: India’s CLABSIs market is USD 132.76 million in 2025, reaching USD 169.31 million by 2034, growing at a CAGR of 2.7%, driven by increasing critical care units.

Respiratory Infections (including VAP): Ventilator-associated pneumonia (VAP) and nosocomial respiratory infections represent a significant share of ICU HAIs: VAP incidence varied between 5–20 cases per 1,000 ventilator days in published surveillance, and ventilator care bundles reduced VAP rates by 30–50% in many centers. Respiratory diagnostics (rapid PCR for multiplex respiratory pathogens) were adopted by roughly 35% of tertiary care labs in 2023, driving consumable and instrument purchases in the Hospital Acquired Infection Control Market.

The Respiratory Infections segment is projected to witness steady growth with a market size of USD 1296.81 million in 2025, rising to USD 1666.30 million by 2034, at a CAGR of 2.8%, driven by post-surgical pneumonia control.

Top 5 Major Dominant Countries in the Respiratory Infections Segment

• United States: The U.S. market size is USD 471.36 million in 2025, projected to reach USD 609.42 million by 2034, growing at CAGR 2.9%, fueled by stringent air quality control in hospitals.
• China: China’s market stands at USD 206.48 million in 2025, rising to USD 268.49 million by 2034, at a CAGR of 2.8%, driven by respiratory infection prevention policies.
• Japan: Japan’s respiratory infection control market is USD 161.34 million in 2025, reaching USD 207.32 million by 2034, with a CAGR of 2.7%, supported by advanced hospital hygiene protocols.
• Germany: Germany’s market is USD 155.28 million in 2025, projected to hit USD 198.37 million by 2034, at 2.7% CAGR, backed by infection control technology adoption.
• India: India records USD 139.17 million in 2025, reaching USD 182.70 million by 2034, at CAGR 2.8%, supported by government-led hospital infection prevention schemes.

BY APPLICATION

Hospitals and ICUs: Hospitals and ICUs are the largest application for infection control solutions: acute care hospitals account for more than 60% of advanced diagnostic and device spend, with ICUs comprising 15–20% of beds but contributing roughly 40% of HAI incidents attributed to device use. In 2023, about 1 in 31 hospitalized patients had an HAI on any given day in U.S. acute care settings, prompting procurement of surveillance, PPE and rapid testing integrated into ICU workflows.

The Hospitals and ICUs segment dominates the market with a market size of USD 3656.12 million in 2025, projected to reach USD 4753.81 million by 2034, at a CAGR of 2.9%, driven by infection prevention mandates.

Top 5 Major Dominant Countries in the Hospitals and ICUs Application

• United States: The U.S. market is USD 1289.36 million in 2025, reaching USD 1678.54 million by 2034, growing at a CAGR of 3.0%, supported by stringent hospital sanitation standards.
• Germany: Germany’s market is USD 482.37 million in 2025, projected to reach USD 618.71 million by 2034, at CAGR 2.9%, driven by infection control audits.
• China: China’s market stands at USD 439.52 million in 2025, increasing to USD 577.12 million by 2034, at CAGR 2.9%, due to healthcare infrastructure expansion.
• France: France’s market is USD 367.41 million in 2025, reaching USD 473.25 million by 2034, at CAGR 2.8%, backed by hygiene compliance initiatives.
• India: India’s market is USD 333.18 million in 2025, reaching USD 423.19 million by 2034, growing at a CAGR of 2.8%, driven by infection control modernization.

Outpatient Care Centers: Outpatient care centers (surgical centers, dialysis clinics) increased infection control procurement by 18% in 2023 as procedural volumes rose; ambulatory surgical centers purchased 22% more single-use sterile sets and 16% more environmental cleaning products year-on-year. Dialysis clinics specifically reported an uptick in bloodstream infection surveillance, with 12% of clinics adopting centralized reporting systems in 2023.

The Outpatient Care Centers segment holds a market size of USD 1452.61 million in 2025, estimated to reach USD 1842.76 million by 2034, growing at a CAGR of 2.7%, due to increased procedural sterilization needs.

Top 5 Major Dominant Countries in the Outpatient Care Centers Application

• United States: The U.S. market is USD 512.34 million in 2025, reaching USD 662.48 million by 2034, growing at CAGR 2.8%, led by stringent outpatient sterilization standards.
• Germany: Germany’s market is USD 248.25 million in 2025, increasing to USD 314.26 million by 2034, at CAGR 2.7%, supported by outpatient infection control compliance.
• China: China’s market is USD 221.46 million in 2025, reaching USD 284.68 million by 2034, growing at 2.7% CAGR, driven by rapid outpatient service growth.
• France: France holds USD 198.73 million in 2025, estimated to reach USD 251.72 million by 2034, at 2.7% CAGR, supported by safety-focused ambulatory care growth.
• India: India’s market is USD 179.83 million in 2025, rising to USD 229.62 million by 2034, with CAGR 2.6%, driven by private outpatient facility expansion.

Long-term Care Facilities (LTCFs): LTCFs face high HAI prevalence and rising AMR burden: in many systems LTCFs represent 25–30% of institutional HAI incidence by facility count, and environmental cleaning and staff training purchases increased by 14% in 2023. Adoption of point-prevalence surveys in LTCFs rose to 20% in 2023, with sample sizes often covering 50–500 residents per survey, shaping demand in the Hospital Acquired Infection Control Market for mobile diagnostics and turnkey training programs.

The LTCFs segment is projected at USD 1125.62 million in 2025, expected to reach USD 1462.30 million by 2034, growing at a CAGR of 2.9%, driven by rising geriatric care and infection control awareness.

Top 5 Major Dominant Countries in the Long-term Care Facilities (LTCFs) Application

• United States: The U.S. market is USD 384.72 million in 2025, reaching USD 507.54 million by 2034, growing at CAGR 2.9%, due to improved elderly infection prevention programs.
• Germany: Germany’s LTCFs market is USD 206.19 million in 2025, projected to hit USD 268.32 million by 2034, at CAGR 2.8%, driven by hygiene modernization in care homes.
• Japan: Japan’s market is USD 192.73 million in 2025, reaching USD 250.18 million by 2034, with a CAGR of 2.9%, supported by advanced aging population care standards.
• France: France holds USD 179.64 million in 2025, expected to reach USD 232.18 million by 2034, with CAGR 2.8%, due to enhanced LTC hygiene protocols.
• India: India’s LTCFs market is USD 162.34 million in 2025, projected to reach USD 204.08 million by 2034, growing at CAGR 2.7%, driven by expanding eldercare infrastructure.

Hospital Acquired Infection Control Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America leads in adoption of advanced Hospital Acquired Infection Control Market technologies: 34% of global high-end diagnostic and disinfection procurement occurred here in 2023, and 60–80% of large health systems set compliance targets for infection prevention bundles. U.S. surveillance systems reported that on any given day 1 in 31 hospitalized patients had an HAI, prompting investments in automated environmental disinfection and molecular diagnostics; hospital tenders for bundled surveillance-disinfection contracts rose by 27% in 2024.

The North America Hospital Acquired Infection Control Market is projected to reach USD 2457.63 million by 2034 from USD 1898.45 million in 2025, growing at a CAGR of 2.9%, driven by stringent infection prevention regulations and robust healthcare infrastructure.

North America - Major Dominant Countries in the “Hospital Acquired Infection Control Market”

• United States: The U.S. market is valued at USD 1287.41 million in 2025, reaching USD 1664.53 million by 2034, with a CAGR of 3.0%, supported by advanced infection control technologies and regulatory compliance.
• Canada: Canada’s market stands at USD 289.72 million in 2025, projected to hit USD 375.29 million by 2034, growing at CAGR 2.8%, driven by enhanced hospital sanitation and safety protocols.
• Mexico: Mexico’s market is USD 167.94 million in 2025, expected to reach USD 217.81 million by 2034, at CAGR 2.9%, influenced by increased hospital infrastructure investments and infection monitoring programs.
• Cuba: Cuba’s market size is USD 74.85 million in 2025, reaching USD 95.64 million by 2034, growing at CAGR 2.8%, supported by public healthcare improvements and infection reduction campaigns.
• Costa Rica: Costa Rica records USD 78.53 million in 2025, estimated to reach USD 104.36 million by 2034, with CAGR 2.9%, driven by healthcare modernization and infection prevention initiatives.

EUROPE

Europe represents a mature Hospital Acquired Infection Control Market with widespread regulatory frameworks and national reporting: EU/EEA prevalence surveys indicate roughly 4.3 million HAI events annually, and 28% of hospital procurement tends to prioritize low-emission and validated environmental interventions. In 2023, 32% of newly purchased infection control devices in Europe met enhanced low-NOx or eco-certification standards, and 21% of hospitals added automated disinfection or ATP surface monitoring in 2024.

The Europe Hospital Acquired Infection Control Market is projected to increase from USD 1643.26 million in 2025 to USD 2136.45 million by 2034, expanding at a CAGR of 2.8%, supported by EU-wide infection surveillance systems and hygiene mandates.

Europe - Major Dominant Countries in the “Hospital Acquired Infection Control Market”

• Germany: Germany’s market is USD 493.17 million in 2025, expected to reach USD 639.58 million by 2034, with CAGR 2.8%, driven by strong infection prevention policies in public healthcare.
• France: France holds USD 368.45 million in 2025, increasing to USD 475.31 million by 2034, growing at CAGR 2.9%, supported by modern sterilization technology adoption and hospital hygiene audits.
• United Kingdom: The UK’s market is USD 322.64 million in 2025, projected to reach USD 417.26 million by 2034, at a CAGR of 2.8%, driven by strict NHS infection control standards.
• Italy: Italy’s market stands at USD 254.72 million in 2025, reaching USD 330.17 million by 2034, at a CAGR of 2.9%, boosted by improvements in ICU disinfection protocols.
• Spain: Spain’s market size is USD 204.28 million in 2025, estimated to hit USD 274.13 million by 2034, with CAGR 2.8%, fueled by advanced infection prevention in surgical units.

ASIA-PACIFIC

Asia-Pacific commanded roughly 36% of global unit purchases in the Hospital Acquired Infection Control Market in 2023, driven by high patient volumes and expansion of hospital capacity: numerous countries added tens to hundreds of thousands of hospital beds between 2020–2023, and adoption of basic infection control consumables surged by 19% in 2023. 

The Asia Hospital Acquired Infection Control Market is expected to grow from USD 1462.18 million in 2025 to USD 1927.13 million by 2034, recording a CAGR of 3.0%, owing to rapid healthcare expansion, rising awareness, and stricter hospital hygiene compliance.

Asia - Major Dominant Countries in the “Hospital Acquired Infection Control Market”

• China: China’s market stands at USD 524.61 million in 2025, reaching USD 698.42 million by 2034, growing at CAGR 3.1%, driven by hospital modernization and infection surveillance programs.
• India: India’s market is USD 397.38 million in 2025, projected to reach USD 528.72 million by 2034, at a CAGR of 3.1%, supported by growing investments in infection control infrastructure.
• Japan: Japan’s market is USD 286.52 million in 2025, expected to reach USD 366.47 million by 2034, with CAGR 2.9%, influenced by advanced infection detection and prevention technologies.
• South Korea: South Korea’s market stands at USD 164.71 million in 2025, projected to hit USD 211.68 million by 2034, growing at CAGR 2.8%, supported by hospital hygiene automation systems.
• Indonesia: Indonesia’s market is USD 89.26 million in 2025, increasing to USD 122.84 million by 2034, growing at CAGR 3.0%, driven by infection control initiatives in government hospitals.

MIDDLE EAST & AFRICA

Middle East & Africa exhibited project-driven procurement patterns, accounting for roughly 12–14% of global emergency infection-control deployments in 2023. The Gulf Cooperation Council hosted over 200 hospital development or refurbishment projects in 2023, many specifying advanced disinfection and isolation solutions; these projects increased demand for negative-pressure rooms and automated decontamination systems by 18%.

The Middle East and Africa Hospital Acquired Infection Control Market is forecasted to expand from USD 1230.20 million in 2025 to USD 1537.66 million by 2034, witnessing a CAGR of 2.6%, due to increased healthcare spending and infection awareness programs.

Middle East and Africa - Major Dominant Countries in the “Hospital Acquired Infection Control Market”

• Saudi Arabia: Saudi Arabia’s market is USD 368.35 million in 2025, expected to reach USD 470.16 million by 2034, at CAGR 2.8%, driven by rising infection control measures in large hospitals.
• United Arab Emirates: The UAE’s market stands at USD 287.43 million in 2025, projected to hit USD 366.41 million by 2034, with CAGR 2.7%, supported by improved infection surveillance infrastructure.
• South Africa: South Africa’s market is USD 219.54 million in 2025, growing to USD 272.67 million by 2034, at CAGR 2.5%, fueled by hospital hygiene standardization initiatives.
• Egypt: Egypt’s market stands at USD 195.21 million in 2025, expected to reach USD 244.72 million by 2034, with CAGR 2.6%, aided by expanding healthcare safety programs.
• Qatar: Qatar’s market is USD 159.67 million in 2025, projected to reach USD 183.70 million by 2034, growing at CAGR 2.5%, supported by healthcare quality improvement programs.

List of Top Hospital Acquired Infection Control Companies

• Pfizer
• Roche
• Merck
• Johnson & Johnson
• Abbott
• Bayer
• BD (Becton Dickinson)
• Kimberly-Clark
• Nordion
• Cepheid

Johnson & Johnson: estimated to hold a leading position in medical device and infection-control consumables with roughly 12–14% share in consumables and procedural infection-support sales in hospital channels in 2023.

BD (Becton Dickinson): estimated to account for approximately 10–12% share in diagnostic consumables and device markets for infection control in hospital settings in 2023.

Investment Analysis and Opportunities

Investment opportunities in the Hospital Acquired Infection Control Market focus on diagnostics, tele-surveillance, and bundled service contracts. Rapid molecular diagnostics comprised roughly 35% of new instrument procurement by tertiary centers in 2023, and point-of-care test volume rose about 22% year-on-year in 2023–2024. Tele-surveillance and AI predictive analytics pilots covered approximately 18% of large hospital networks in 2023 and are expected to scale as integration improves; integrated bundles (diagnostics + disinfection + surveillance) accounted for 25% of awarded contracts in 2024. 

New Product Development

New product development in the Hospital Acquired Infection Control Market emphasises speed, automation and environmental safety: in 2023–2024 about 41% of launches were for rapid diagnostics, automated room disinfection systems or antimicrobial surface treatments. Molecular multiplex panels with turnaround times under 60 minutes were introduced in 35% of tertiary labs, and portable PCR platforms accounted for 18% of new instrument orders among point-of-care buyers.

Five Recent Developments

• In 2024 a health system group deployed automated UV-C room disinfection units across 120 hospital sites, representing a 19% increase in automated disinfection usage within that network.
• In 2023 a diagnostic vendor shipped over 2,500 rapid molecular POC units globally, increasing hospital lab rapid testing capacity by approximately 22% in targeted regions.
• In 2025 several tertiary centers reported adoption of AI-driven HAI surveillance modules covering 18% of national network beds in pilot implementations.
• In 2024 a consortium of hospitals increased antimicrobial stewardship staffing by 44%, leading to a 12% reduction in broad-spectrum antibiotic days in participating facilities.
• In 2023–2024 procurement consortia aggregated purchases of disinfectant consumables across 300 smaller hospitals, reducing per-unit procurement cycles by 15% and accelerating supply continuity.

Report Coverage of Hospital Acquired Infection Control Market

The Hospital Acquired Infection Control Market Research Report covers product segmentation (diagnostics, disinfection systems, surveillance software, consumables and training), application segmentation (hospitals and ICUs, outpatient care centers, LTCFs), and regional analysis (North America, Europe, Asia-Pacific, Middle East & Africa). It includes prevalence and burden data—WHO and national surveys indicating 1 in 10 patients in low-income settings and 4.3 million HAIs annually in EU/EEA hospitals—alongside procurement and adoption metrics such as 19% growth in automated disinfection purchases in 2024 and 35% rapid diagnostic uptake in tertiary labs.

Hospital Acquired Infection Control Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 6415.15 Million in 2026
Market Size Value By	USD 8292.58 Million by 2035
Growth Rate	CAGR of 2.9% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Catheter-associated Urinary Tract Infections (CAUTIs) Surgical Site Infections (SSIs) Central Line-associated Bloodstream Infections (CLABSIs) Respiratory Infections By Application : Hospitals and ICUs Outpatient Care Centers Long-term Care Facilities (LTCFs)
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample